CONSULTING AGREEMENTConsulting Agreement • July 13th, 2023 • HWEL Holdings Corp. • Pharmaceutical preparations • New York
THIS CONSULTING AGREEMENT (“Agreement”) is made effective as of the 1st day of July 2018, by and between ChemioCare, with an address at 322 W 57th St. Apt 35B, New York, NY 10019 (“Client”), and ATR Consultants LLC (“Consultant”).
EXCHANGEABLE SHARE SUPPORT AGREEMENTExchangeable Share Support Agreement • September 21st, 2023 • HWEL Holdings Corp. • Pharmaceutical preparations • British Columbia
This Exchangeable Share Support Agreement made as of ●, 2023 among HWEL Holdings Corp., a corporation existing under the laws of the State of Delaware (“Parent”), 1412384 B.C. Unlimited Liability Company, an unlimited liability corporation existing under the laws of the Province of British Columbia (“Callco”), and 1412388 B.C. Ltd., a corporation existing under the laws of the Province of British Columbia (the “Company”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • July 13th, 2023 • HWEL Holdings Corp. • Pharmaceutical preparations • New York
This Executive Employment Agreement (the “Agreement”) is made as of September 1, 2022 (the “Start Date”) by and between Starton Therapeutics, Inc., a corporation with its principal place of business located at 215 College Road, Suite #300, Paramus, New Jersey (the “Company”), and James C. Oliver, an individual residing at 4100 City of Oaks Wynd, Raleigh, NC 27612 (the “Executive”).
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • July 13th, 2023 • HWEL Holdings Corp. • Pharmaceutical preparations • New York
This Executive Employment Agreement (the “Agreement”) is made effective as of April 27, 2023 by and between Starton Therapeutics, Inc., a Delaware corporation with its principal place of business located in New Jersey (the “Company”), and Pedro Lichtinger Waisman, an individual residing at 18975 Collins Avenue, Apartment 1201, Sunny Isles Beach, FL 33160 (the “Executive”).
DEVELOPMENT AND COMMERCIAL LICENSE AGREEMENT By and among STARTON THERAPEUTICS, INC. and HAISCO PHARMACEUTICAL GROUP CO., LTDDevelopment and Commercial License Agreement • July 13th, 2023 • HWEL Holdings Corp. • Pharmaceutical preparations
This DEVELOPMENT AND COMMERCIAL LICENSE AGREEMENT (together with all Exhibits, this “Agreement”) is entered into on this 10th day of February, 2021 (the “Effective Date”), by and among STARTON THERAPEUTICS, INC., a Delaware corporation with its principal place of business at 215 College Road, Suite 300, Paramus, New Jersey 07652 (“Starton”), and HAISCO PHARMACEUTICAL GROUP Co., Ltd., a corporation incorporated under the laws of the People’s Republic of China with its principal place of business at No. 136 Baili Road CNSTP, Wenjiang District, Chengdu, Sichuan Province 611130 (“Haisco”). Haisco and Starton may each be referred to herein individually as a “Party” and collectively as the “Parties.”
AGREEMENTHWEL Holdings Corp. • July 13th, 2023 • Pharmaceutical preparations • New York
This (“Agreement”) is made as of September 9, 2019 (“Effective Date”) between ChemioCareInc. (“ChemioCare”), and Alpha to Omega Pharmaceutical Consultants, Inc. (“AOPC”) Chemiocare or AOPC may hereafter be referred to individually as a “Party” and collectively as the “Parties.”
RESEARCH SERVICE CONTRACTHWEL Holdings Corp. • July 13th, 2023 • Pharmaceutical preparations
a corporation incorporated under the laws of Delaware, having an office for the conduct of its business located at 322 W 57th St, Apt 35B, New York, New York, USA, 10019 (the “SPONSOR”)
